634 related articles for article (PubMed ID: 30447069)
1. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and pharmacogenetics of thiopurines.
Sahasranaman S; Howard D; Roy S
Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Hindorf U; Lindqvist M; Peterson C; Söderkvist P; Ström M; Hjortswang H; Pousette A; Almer S
Gut; 2006 Oct; 55(10):1423-31. PubMed ID: 16543290
[TBL] [Abstract][Full Text] [Related]
5. Implementation of TPMT testing.
Lennard L
Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon.
Ferreira GMA; Ribeiro Elias AB; Nascimento J; Monteiro WM; Melo GC; Baia-da-Silva DC; Lacerda MVG; Suarez-Kurtz G
Pharmacogenet Genomics; 2020 Oct; 30(8):184-189. PubMed ID: 32453263
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.
Lennard L
Ther Drug Monit; 1998 Oct; 20(5):527-31. PubMed ID: 9780130
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.
Suarez-Kurtz G; Araújo GS; de Sousa SJ
Pharmacogenet Genomics; 2020 Jan; 30(1):1-4. PubMed ID: 31651720
[TBL] [Abstract][Full Text] [Related]
10. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
11. Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.
Liu C; Yang W; Pei D; Cheng C; Smith C; Landier W; Hageman L; Chen Y; Yang JJ; Crews KR; Kornegay N; Karol SE; Wong FL; Jeha S; Sandlund JT; Ribeiro RC; Rubnitz JE; Metzger ML; Pui CH; Evans WE; Bhatia S; Relling MV
Clin Pharmacol Ther; 2017 Mar; 101(3):373-381. PubMed ID: 27564568
[TBL] [Abstract][Full Text] [Related]
12. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
14. Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong VW; Shipkova M; von Ahsen N; Oellerich M
Ther Drug Monit; 2004 Apr; 26(2):220-6. PubMed ID: 15228169
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
Chang JY; Cheon JH
Dig Dis Sci; 2019 Sep; 64(9):2395-2403. PubMed ID: 31290039
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
17. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
McLeod HL; Krynetski EY; Relling MV; Evans WE
Leukemia; 2000 Apr; 14(4):567-72. PubMed ID: 10764140
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Díaz-Villamarín X; Fernández-Varón E; Rojas Romero MC; Callejas-Rubio JL; Cabeza-Barrera J; Rodríguez-Nogales A; Gálvez J; Morón R
Biomed Pharmacother; 2023 Dec; 168():115706. PubMed ID: 37857254
[TBL] [Abstract][Full Text] [Related]
19. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.
Liang DC; Yang CP; Liu HC; Jaing TH; Chen SH; Hung IJ; Yeh TC; Lin TH; Lai CL; Lai CY; Shih LY
Pharmacogenomics J; 2016 Nov; 16(6):536-539. PubMed ID: 26503813
[TBL] [Abstract][Full Text] [Related]
20. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
